The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).
Manisha H. Shah
Disclosure not yet available
Tetsuhide Ito
Disclosure not yet available
Catherine Lombard-Bohas
Disclosure not yet available
Edward M. Wolin
Disclosure not yet available
Eric Van Cutsem
Disclosure not yet available
Carolin Sachs
Disclosure not yet available
Robert E. Winkler
Disclosure not yet available
Jeremie Lincy
Disclosure not yet available
Timothy J. Hobday
Disclosure not yet available
James C. Yao
Disclosure not yet available